Brainstorm Cell Therapeutics (NASDAQ:BCLI) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research note issued to investors on Wednesday morning.

Brainstorm Cell Therapeutics Stock Up 0.8 %

BCLI stock opened at $1.25 on Wednesday. Brainstorm Cell Therapeutics has a 12-month low of $1.05 and a 12-month high of $11.89. The firm has a market cap of $7.13 million, a PE ratio of -0.26 and a beta of 0.40. The business has a 50 day moving average of $2.24 and a 200-day moving average of $4.54.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

A hedge fund recently bought a new stake in Brainstorm Cell Therapeutics stock. Armistice Capital LLC acquired a new position in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 7,917,653 shares of the biotechnology company’s stock, valued at approximately $2,680,000. Armistice Capital LLC owned 11.30% of Brainstorm Cell Therapeutics at the end of the most recent quarter. 14.33% of the stock is currently owned by institutional investors and hedge funds.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.